Shared heritability of attention-deficit/ hyperactivity disorder and autism spectrum disorder by Rommelse, Nanda N. J. et al.
www.ssoar.info
Shared heritability of attention-deficit/ hyperactivity
disorder and autism spectrum disorder
Rommelse, Nanda N. J.; Franke, Barbara; Geurts, Hilde M.; Hartman,
Catharina A.; Buitelaar, Jan K.
Postprint / Postprint
Zeitschriftenartikel / journal article
Zur Verfügung gestellt in Kooperation mit / provided in cooperation with:
www.peerproject.eu
Empfohlene Zitierung / Suggested Citation:
Rommelse, N. N. J., Franke, B., Geurts, H. M., Hartman, C. A., & Buitelaar, J. K. (2010). Shared heritability of
attention-deficit/ hyperactivity disorder and autism spectrum disorder. European Child & Adolescent Psychiatry, 19(3),
281-295. https://doi.org/10.1007/s00787-010-0092-x
Nutzungsbedingungen:
Dieser Text wird unter dem "PEER Licence Agreement zur
Verfügung" gestellt. Nähere Auskünfte zum PEER-Projekt finden
Sie hier: http://www.peerproject.eu Gewährt wird ein nicht
exklusives, nicht übertragbares, persönliches und beschränktes
Recht auf Nutzung dieses Dokuments. Dieses Dokument
ist ausschließlich für den persönlichen, nicht-kommerziellen
Gebrauch bestimmt. Auf sämtlichen Kopien dieses Dokuments
müssen alle Urheberrechtshinweise und sonstigen Hinweise
auf gesetzlichen Schutz beibehalten werden. Sie dürfen dieses
Dokument nicht in irgendeiner Weise abändern, noch dürfen
Sie dieses Dokument für öffentliche oder kommerzielle Zwecke
vervielfältigen, öffentlich ausstellen, aufführen, vertreiben oder
anderweitig nutzen.
Mit der Verwendung dieses Dokuments erkennen Sie die
Nutzungsbedingungen an.
Terms of use:
This document is made available under the "PEER Licence
Agreement ". For more Information regarding the PEER-project
see: http://www.peerproject.eu This document is solely intended
for your personal, non-commercial use.All of the copies of
this documents must retain all copyright information and other
information regarding legal protection. You are not allowed to alter
this document in any way, to copy it for public or commercial
purposes, to exhibit the document in public, to perform, distribute
or otherwise use the document in public.
By using this particular document, you accept the above-stated
conditions of use.
Diese Version ist zitierbar unter / This version is citable under:
https://nbn-resolving.org/urn:nbn:de:0168-ssoar-215913
REVIEW
Shared heritability of attention-deficit/hyperactivity disorder
and autism spectrum disorder
Nanda N. J. Rommelse • Barbara Franke •
Hilde M. Geurts • Catharina A. Hartman •
Jan K. Buitelaar
Received: 12 August 2009 / Accepted: 8 January 2010 / Published online: 11 February 2010
 The Author(s) 2010. This article is published with open access at Springerlink.com
Abstract Attention-deficit/hyperactivity disorder (ADHD)
and autism spectrum disorder (ASD) are both highly heri-
table neurodevelopmental disorders. Evidence indicates
both disorders co-occur with a high frequency, in 20–50%
of children with ADHD meeting criteria for ASD and in 30-
80% of ASD children meeting criteria for ADHD. This
review will provide an overview on all available studies
[family based, twin, candidate gene, linkage, and genome
wide association (GWA) studies] shedding light on the role
of shared genetic underpinnings of ADHD and ASD. It is
concluded that family and twin studies do provide support
for the hypothesis that ADHD and ASD originate from
partly similar familial/genetic factors. Only a few candidate
gene studies, linkage studies and GWA studies have spe-
cifically addressed this co-occurrence, pinpointing to some
promising pleiotropic genes, loci and single nucleotide
polymorphisms (SNPs), but the research field is in urgent
need for better designed and powered studies to tackle this
complex issue. We propose that future studies examining
shared familial etiological factors for ADHD and ASD use a
family-based design in which the same phenotypic (ADHD
and ASD), candidate endophenotypic, and environmental
measurements are obtained from all family members.
Multivariate multi-level models are probably best suited for
the statistical analysis.
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Introduction
Based on their diagnostic descriptions, attention-deficit/
hyperactivity disorder (ADHD) and Autism Spectrum
Disorder (ASD) have little in common. ADHD is
characterized by severe inattention, hyperactivity, and
impulsivity, whereas ASD is characterized by impaired
communication and social interaction skills, as well as
repetitive and restricted behavior and interests [3]. How-
ever, in clinical practice it is commonly observed that a
child with ADHD shows symptoms of ASD and vice versa.
Moreover, ADHD and ASD appear to co-occur in families,
with one child for instance having ADHD and the other
child having ASD or a combination of both disorders.
Despite these clinical observations, the diagnostic
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guidelines in the Diagnostic and Statistical Manual of
Mental Disorders 4th edition (DSM-IV) [3] prevent making
a comorbid diagnosis, based on the rationale that ADHD-
like symptoms in patients with ASD are primarily attrib-
utable to the ASD diagnosis. This argument is widely
disputed, and it is now commonly believed that both dis-
orders can co-occur.
Several studies have made an estimation of the co-
occurrence rates of ADHD and ASD, by examining the
prevalence of ASD in ADHD samples and vice versa.
Estimations vary substantially; based on the lowest and
highest reported prevalence rates, 20–50% of children with
ADHD meet criteria for ASD and 30-80% of ASD children
meet criteria for ADHD [20, 32, 43, 47, 51, 81, 86, 88,
100]. Much less is known about co-occurrence rates in
adults. Two studies indicate that 40–50% of patients with
autistic disorder or atypical autism, 28–36% of patients
with Asperger syndrome and around 52% of patients with
PDD-NOS, fulfill the criteria for ADHD (including ADHD
in remission) [4, 46]. The interpretation of comorbidity
rates from clinical samples, however, is limited due to
possible referral bias. A further complicating factor in all
of these studies, is the entanglement of symptom descrip-
tions of both disorders. That is, inattention (a core symp-
tom of ADHD) can easily be mistaken for social inattention
(a core symptom of ASD), resulting in inflated co-occur-
rence rates of both disorders. Ideally, prevalence rates of
ADHD in ASD are calculated both in a loose manner and a
stringent manner, in which the latter refers to correcting for
the population prevalence of ADHD when calculating
prevalence rates of ADHD in an ASD sample and vice
versa. Or, even better, a factor analysis on a pool of ADHD
and ASD items should be performed, excluding the items
that show too much cross-correlation, in order to extract
more pure constructs of ADHD and ASD. Such a stringent
approach to study the co-occurrence of ADHD and ASD,
however, has yet to be performed. Nevertheless, despite the
shortcomings of the studies reporting on co-occurrence
rates of ADHD and ASD, it is undeniable that both dis-
orders can co-occur in the same patient.
However, due to the DSM-IV diagnostic restrictions, little
is known about the nature of the co-occurrence of ADHD
and ASD. The co-occurrence of two disorders may be
caused by a variety of reasons. First, as mentioned above, it
may be related to overlapping diagnostic criteria, resulting
in inflated co-occurrence rates. As far as the authors know,
no studies exist that have performed a factor analysis on
ADHD and ASD DSM-IV derived items to examine the
extent of overlapping diagnostic criteria. Even though it is of
vital concern to examine the interrelatedness of both con-
struct descriptions, we do not believe the co-occurrence of
ADHD and ASD can be completely explained by overlap-
ping diagnostic criteria. Second, co-occurrence of ADHD
and ASD may be caused by one disorder leading to the other.
In this scenario, treatment of one disorder might improve
symptoms of the other disorder as well. This appears not to
be the case: Psychostimulants and noradrenergic reuptake
inhibitors appear effective in the treatment of ADHD
symptoms in patients with a combined diagnosis of
ADHD ? ASD, but do not have a substantial effect on the
ASD symptoms [2, 41, 70, 83, 95]. Also the age of onset and
developmental sequence of ASD and ADHD do not support
a likely model of one disorder leading to the other. For ASD
has by definition an earlier onset than ADHD, and would
then be causing ADHD. However, in most if not all ASD
plus ADHD cases the first clinical presentation includes the
simultaneous expression of ASD and ADHD symptoms.
Another theoretical possibility is that one of the disorders
produces a phenocopy of the other. A phenocopy is an
individual whose phenotype, under a particular environ-
mental condition, is identical to the one of another indi-
vidual whose phenotype is determined by the genotype. In
other words, the phenocopy environmental condition mim-
ics the phenotype produced by a gene. An example of a
phenocopy in the context of this paper would be a child with
a strong genetic predisposition for ADHD but growing up in
a rigid, bizar, and unempathic family. This could lead to the
expression of the ADHD phenotype, on the basis of the
genotype, in addition to the expression of an ASD pheno-
type, on the basis of the specific environmental condition.
This does not seem to be a likely model, however. Two final
explanations for the co-occurrence of ADHD and ASD may
be that they are separable and independent disorders
occurring together—for example by their association with a
third independent factor—or alternatively, they share a
common underlying etiology [6, 10, 15, 19, 36]. We believe
that the latter is true and the most likely model, and that both
disorders partly shared a common genetic basis. This will be
the main topic of the current review.
Both ADHD and ASD are disorders with a strong her-
itable component. In ADHD, approximately 76% of the
phenotypic variance is explained by heritable factors [29];
in ASD, heritability has been estimated as [90% for the
narrow sense phenotype of classic autism [33], but may be
lower for the broad sense phenotype (although the broad
sense phenotype is more prevalent amongst first- and sec-
ond-degree relatives of ASD probands [69]). For both
disorders, oligogenic and multifactorial modes of inheri-
tance have been proposed, but relatively little progress has
yet been made in identifying the genes involved [31, 33].
This may be (partly) due to clinical and genetic heteroge-
neity [55] as well as to other factors [18]. How then should
we proceed in our search for common genetic risk factors
for ADHD and ASD? We will try to answer this question
by systematically reviewing the literature for studies that
have examined ADHD and ASD in a family-based design
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or in a twin design. The former will provide insight into the
familiality (caused by both heritable factors as well as
shared environmental factors) of ADHD ? ASD. The lat-
ter more directly examines the extent of common genetic
factors underlying ADHD ? ASD, but has the disadvan-
tage that findings are most often based on community
samples instead of clinical samples. The disadvantage of
community twin samples is that they have a very low rate
of clinical disorders such as ASD. Community twin sam-
ples are very useful for the study of subclinical traits across
the continuum but much less for clinical disorders as ASD.
In addition, we provide an overview of possible overlap-
ping candidate genes and genome-wide association find-
ings for both disorders. A summary is provided with
candidate endophenotypic measures (heritable, vulnerabil-
ity traits) that may be useful for unraveling the shared
etiological underpinnings of ADHD and ASD. Finally, we
propose several steps for future molecular genetic studies.
By providing a comprehensive overview of the currently
available findings with respect to shared genetic under-
pinnings of ADHD and ASD, the current review aims to
make an important contribution to the research field and
facilitate future genetic studies for ADHD ? ASD.
Familial aggregation
Only two related studies originating from the IMAGE cohort
(International Multicenter ADHD Genetic study) [7] have
examined the rates/severity of ASD in probands with ADHD
and their siblings [61, 64]. Importantly, in both studies,
probands and siblings with full autistic disorder were
excluded from participation. As far as we know, no studies
exist reporting on ADHD in family members of ASD pro-
bands. In the Mulligan et al. study [61], autism symptoms
were measured using the Social Communication Question-
naire (SCQ) and compared in 821 ADHD probands, 1,050
siblings and 149 controls. As expected, probands (males and
females) had higher SCQ scores than siblings and controls.
In turn, affected and unaffected male siblings, but not female
siblings, had higher SCQ scores than controls. The pheno-
typic correlation between ADHD and ASD was also slightly
higher for males (0.63) than females (0.49). The sibling
cross-correlation, indicative of shared familial influences on
ADHD and ASD was 0.18 for males, of which 56% can be
attributed to shared genetic influences on ADHD and ASD.
This percentage has been calculated by a modified method of
the deFries-Fulker analysis. In this analysis, a comparison is
made of the mean symptom scores of the proband and the
sibling with the mean population scores. See Mulligan et al.
[61] for details. These findings suggest that, at least in males,
ASD symptoms are familial within ADHD families which
likely represent genetic rather than shared environmental
factors. While results did not support this hypothesis in
females, it must be noted that due to the large predominance
of male patients in the sample (88%), cross-correlation could
not be robustly estimated and firm conclusions regarding the
shared familiality of ADHD and ASD symptoms in females
cannot be drawn.
In the Nijmeijer et al. study [64], a similar approach was
taken on the Dutch subsample of the IMAGE dataset. ASD
symptoms were measured using the Children’s Social
Behavior Questionnaire (CSBQ) in 256 sibling pairs and
147 controls. Some important differences exist between the
CSBQ used in the Nijmeijer et al. study and the SCQ used in
the Mulligan et al. study. The 49-item CSBQ is an instru-
ment able to measure less severe variants of ASD symp-
tomatology and ASD related problems (such as problems in
executive functioning and disruptive behavior), whereas the
SCQ is designed to measure the more severe ASD charac-
teristics. Furthermore, the CSBQ uses a 3-point Likert-
scale, in contrast to the ‘yes’ and ‘no’ response options used
in the SCQ. Similarly, the study of Mulligan et al. indicated
that both probands and siblings had higher ASD scores than
controls, ADHD and ASD correlated phenotypically (0.40)
and sibling correlations for ASD were significant. Contrary
to the results of the Mulligan study was the finding that the
sibling correlations for ASD were higher in female pro-
bands (0.44) than male probands (0.23), suggesting ASD to
be more highly familial in females with ADHD compared to
males with ADHD. In addition, sibling correlations for ASD
were generally higher in older than younger children, pos-
sibly indicating an increased genetic influence on ASD
within ADHD families over time. Last, sibling cross-cor-
relations between ADHD and ASD were non-significant,
suggesting that independent familial factors give rise to
ADHD and ASD. This latter finding contrasts somewhat
with the significant albeit small (r = 0.18) sibling cross-
correlations for ADHD and ASD reported by Mulligan et al.
yet may be explained by the substantially smaller sample
size and use of a qualitatively different questionnaire in the
Nijmeijer et al. study. However, it is safe to say that ASD
symptoms are familial within ADHD families, as indicated
by elevated ASD symptom levels in affected and non-
affected siblings of ADHD probands and significant sibling
correlations. Whether ADHD and ASD symptoms arise
from shared familial (and genetic) origins within clinically
ADHD affected children, and whether this is influenced by
age and gender, remains to be investigated.
Twin studies
Constantino et al. [23] were the first to report shared
additive genetic influences on symptoms of ASD (mea-
sured with the Social Reciprocity Scale) and attention
Eur Child Adolesc Psychiatry (2010) 19:281–295 283
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problems (measured with the Child Behavior Checklist) in
219 pairs of male twins aged 7–15 years. Two recent twin
studies examined more directly the genetic correlations
between ADHD and ASD symptoms [75, 79]. One study
examined parent and teacher reported symptoms of ADHD
(using the Conners’) and ASD (using the Childhood As-
perger Syndrome Test) in a large (N = 6,771) sample of
8 year old twins [79]. Phenotypic correlations between
ADHD and ASD were 0.54 for parent and 0.51 for teacher
data. Genetic correlations between ASD and ADHD
symptoms were all[0.50, suggesting a moderate degree of
overlap between ASD and ADHD, both throughout the
general population and at the quantitative extreme. A
model incorporating additive genetic influences and unique
environmental influences fitted the data best. Findings were
robust for influences of rater, sex, IQ, and comorbid con-
duct problems.
Quite similar results were reported in a study using self
reported measures of ADHD (12 DSM-IV items) and ASD
(Social Responsiveness Scale) in young adult twins
(N = 674) [75]. A bivariate model indicated that the
genetic correlation between ADHD and ASD was 0.72,
suggesting that a substantial proportion of the genetic
influences on self-reported ADHD and ASD symptoms
may be shared between the two disorders. Again, models
with additive genetic effects and unique environmental
effects fitted the data best, with no evidence for sex
differences.
Molecular genetic studies
Candidate genes
Abnormal functioning of catecholaminergic and seroto-
nergic neurotransmission has been reported in both ADHD
and ASD [14, 66, 72]. The main focus in ADHD literature
has been on dopamine related genes, given that alterations
in dopamine neurotransmission is a core feature of ADHD
[94]. The main focus in ASD literature has been on sero-
tonin related genes, given that abnormalities in serotonin
neurotransmission are robustly reported in ASD [48].
Accordingly, genes related to these pathways have been the
prime candidates for molecular investigation in both dis-
orders [5, 87; see also elsewhere in this issue].
Dopamine
The dopamine transporter gene (DAT1), coding for a
sodium-dependent dopamine transporter that mediates re-
uptake of dopamine at the synapse, is associated with
ADHD (see for meta-analysis [37]). The most frequently
studied polymorphism is a 40 base pair (bp) variable
number of tandem repeat (VNTR) in the 30-untranslated
region. The 9- and 10-repeat alleles are the two most
common variants in Caucasians. The 10-repeat is associ-
ated with an increased activity of the transporter, resulting
in less dopamine in the synaptic cleft. A recent study
investigated the association between DAT1 and ADHD
symptomatology in 67 children with ASD [34]. In contrast
to expectations, the 10/10 homozygous ASD children were
rated by mothers as being less inattentive and hyperactive-
impulsive than the 9-repeat carriers. However, given that
findings of the 9- versus 10-repeat allele are also mixed in
ADHD literature (Franke et al. submitted), with the latter
sometimes being the risk variant, other times the protective
variant [37], further studies are needed to clarify the role
that DAT1 may play in relation to ADHD ? ASD
symptomatology.
Another extensively studied candidate gene for ADHD
is the dopamine D4 receptor gene (DRD4). A specific
variant of the DRD4 gene associated with ADHD, as
indicated by meta-analyses [37, 52], is the functional 48 bp
VNTR in exon 3. The 7-repeat allele of this VNTR,
identified as the risk allele for ADHD, produces fewer or
less efficient D4 receptors resulting in less responsiveness
to dopamine stimulation. However, when studied in rela-
tion to ASD, no association was found between this 7-
repeat and autism in 136 autism probands recruited from
the same geographic regions as a previous ADHD study
conducted by the same authors [40], suggesting DRD4 may
not be related to ASD.
The dopamine D3 receptor (DRD3) and the DRD4 have
been classified as D2-like receptors based on their
sequence homologies and similarity of pharmacological
and biochemical properties [76]. A possible association
between ADHD and DRD3 has been reported [41, 76],
although a recent meta-analysis does not indicate DRD3 to
be significantly associated with ADHD [37]. Recently, 132
candidate genes were tested for their association with
ADHD and ASD in a two stage approach [50]. First, single
nucleotide polymorphisms (SNPs) were tested in 144 ASD
patients, 110 ADHD patients, and 404 controls. SNPs
reaching a significant threshold for association (p \ 0.01)
were tested in a second independent sample of 128 ASD
patients, 150 ADHD patients, and two samples of controls
(N = 124 and 149). Results indicated that in the first and
second ASD samples and in a joint statistical analysis, a
significant association with SNP rs167771 located in the
DRD3 gene was found. The DRD3 gene appeared to be
related to stereotyped behavior, liability to side effects of
antipsychotic medication, and movement disorders and
may therefore have important clinical implications for
ASD. Disappointingly, no shared association was found
between ADHD and ASD. However, these results should
be seen in light of virtually no significant SNP findings for
284 Eur Child Adolesc Psychiatry (2010) 19:281–295
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both disorders. As the authors noted themselves, they used
a strict (possibly overly conservative) Bonferroni correc-
tion, making it possible that they missed out on loci that
were associated with ADHD and/or ASD.
Serotonin
ASD is related to serotonergic genes [87]. The human
serotonin transporter is encoded by the SLC6A4, SERT, 5-
HTT genes. The transcriptional activity of this gene is
modulated by a repetitive element of differing length in the
promoter. A short version leads to a limited transcription
and a reduced amount of the transporter. Studies on this
polymorphism in relation to ADHD and ASD have been
reviewed [87]. The authors concluded that although there is
some evidence supporting the association of the polymor-
phism with both ADHD and ASD, a uniform picture does
not emerge and overlap in findings may be best described
by dimensional classification of the two disorders. The
advantage of the dimensional approach is that one takes
full account of all information available. For example,
individuals with moderately high but just subthreshold
scores are lumped together with subjects with low scores in
a categorical approach. In a dimensional approach, the
quantitative difference between subthreshold and low
scores is taken into account. The authors suggest that
studies examining this polymorphism simultaneously in
children with ADHD, ASD, and ADHD ? ASD may be
needed.
Other
Breakdown of the catecholamines dopamine, adrenaline,
and noradrenaline is mediated by the enzyme Catechol-O-
methyltransferase (COMT). Multiple studies have investi-
gated the association between ADHD and a functional
SNP, Val158Met (rs4680), associated with decreased
enzyme activity (Met-allele) and leading to increased intra-
synaptic amount of dopamine in the mesocortical dopa-
mine pathway. Mixed results have been found (see for
review elsewhere in this issue). A recent study reported that
this functional SNP was also related to social phobia in
subjects with ASD [35]. However, no relationship was
found with ADHD measures within the sample, yet given
the small sample size (N = 67) no firm conclusions can be
drawn on the validity of the COMT gene as a pleiotropic
ADHD/ASD gene.
The X-chromosomal gene Monoamine Oxidase A
(MAOA) gene codes for a mitochondrial enzyme involved
in the pre-synaptic degradation of the monoamines sero-
tonin, norepinephrine, and dopamine [24]. The gene is a
candidate for ADHD because it influences those mono-
aminergic systems that are also etiologically related to
ADHD [25] and MAOA activity can be inhibited by
methylphenidate, which also reduces ADHD symptoms.
Several studies have indeed found various polymorphisms
in MAOA (like a 30 bp repeat in the promoter region, a GA
repeat in intron 2, and a G/T in exon 8) to be associated
with ADHD, with small odds ratio’s around 1.31 and 1.94
[17, 25, 26, 40, 55; see also elsewhere in this issue). A
recent study employing a small sample size (N = 43) of
boys with ASD reported an association between the 30 bp
VNTR in the promoter region of the MAOA gene and
severity of ADHD in these boys [80]. As the authors
indicate, these results suggest that behavioral disturbances
in children with and without ASD may share similar
pathogenic mechanisms.
Rare mutations
In some cases, a combined diagnosis of ASD and ADHD
may be attributable to a premutation in the 50 untranslated
region of the FMR1 gene on the X-chromosome. A full
mutation in this region ([200 repeats of a CGG trinu-
cleotide) results in Fragile X syndrome, the most common
heritable form of mental retardation [30]. Most individuals
with fewer repeats (a premutation: 55–200 repeats) suffer
from mild variants of cognitive and behavioral problems
seen in individuals with the full mutation. The prevalence
of the premutation in the general population (1:813 males
and 1:259 females) is much higher than the prevalence of
the full mutation alleles [30], thereby making this premu-
tation more relevant for clinical healthcare. Farzin et al.
[30] showed that in a relatively small sample (N = 43) of
boys (27 premutation carriers and 16 non-carrier siblings),
the premutation was significantly associated with both
clinical diagnosis of ASD as well as ADHD symptoms.
Thus, in some cases, a combined diagnosis may be linked
to premutations in the FMR1 gene on the X-chromosome.
In other rare cases, segmental duplications at break-
points (BP4-BP5) of chromosome 15q13.2-q13.3 may be
the underlying cause of ADHD ? ASD [59]. The proximal
portion of chromosome 15q is a well-known region of
genomic instability that contains many segmental dupli-
cations. Deletions at 15q11-q13 on the known breakpoint
BP1, BP2, and BP3 can result in Prader-Willi syndrome
and Angelman syndrome [59]. A recent study reported on
the clinical features of five patients with a BP4-BP5 dele-
tion, three with a BP4-BP5 duplication, and two with an
overlapping but smaller duplication extracted from a DNA
database of 1,445 unrelated patients submitted consecu-
tively for clinical array comparative genomic hybridisation
(CGH) testing at Children’s Hospital, Boston and of 1,441
individuals with autism from 751 families in the Autism
Genetic Resource Exchange (AGRE) repository. Results
indicated that the phenotype of microdeletions or
Eur Child Adolesc Psychiatry (2010) 19:281–295 285
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duplications at breakpoints BP4 and BP5 were related to
ASD, ADHD, minor dysmorphic features, expressive lan-
guage deficits and cognitive impairment [59].
A deletion of 22q11 (containing the COMT gene) may
also be underlying ADHD ? ASD in some rare cases. In
100 cases with this deletion, the known cause of velocar-
diofacial (VCF) or DiGeorge syndrome, 44% were diag-
nosed with at least one of both disorders [65]. Nine percent
of cases had a combined diagnosis. In addition, mental
retardation was also common.
The rare XXYY syndrome (prevalence 1:18,000–
40,000) may account for a few ADHD ? ASD cases as
well. In 95 males with this syndrome, over 72% had ADHD
and over 28% had ASD [92]. However, given that this
syndrome is accompanied by characteristic physical and
facial abnormalities (such as tall stature, hypogonadism,
dental problems, seizures, infertility) and almost half of the
patients show clear white matter abnormalities and
enlarged ventricles [92], this syndrome is unlikely to
account for many ADHD ? ASD cases without clear
medical cause. In fact, this conclusion holds for most of the
aforementioned rare mutations.
Recently, a plethora of new information on rare muta-
tions (copy number variations, CNVs) and their possible
role in ASD has been generated by the genome-wide copy
number analyses [17, 22, 38, 57, 85, 102; see also the
Autism Chromosome Rearrangement Database (http://
projects.tcag.ca/autism/)]. These studies suggest that a
considerable number of ASD cases may be explained by
rare genetic variants of intermediate to large effect size.
One recent study also reports on genome-wide CNV
analysis in ADHD [28]. These findings also help to clarify
the joint etiology of ADHD and ASD, which remains to be
investigated. Interestingly, though, in the study by Elia
et al. [28] CNVs segregating with ADHD were found to be
enriched for ASD candidate genes, while in several of the
ASD CNV studies, family members of the ASD patients
also carrying the CNV had diagnoses of ADHD [57, 98].
Possible overlapping linkage findings
Linkage studies have been performed to identify new
chromosomal loci harboring risk genes for ADHD and
ASD. With the exception of one study, only an indirect
comparison of candidate linkage loci for ADHD and ASD
can be made, since all loci are based on studies including
patients with either ADHD or ASD. In the latter case,
probably ADHD ? ASD cases were included, but this was
not systematically registered or measured. The linkage
study by Bakker et al. [9] analyzed both a narrow pheno-
type, in which only sib pairs with ADHD were included
(N = 117), and a broad phenotype, containing additional
sib pairs (N = 47), in which one child had an spectrum
disorder but also met the full ADHD criteria. For this broad
phenotype, suggestive linkage was observed on chromo-
some 15q15. An overview of the ADHD- or ASD-specific
literature provides limited supporting evidence for overlap.
When applying a threshold of 2.2 for the multipoint loga-
rithm of odds score (MLS), indicative of suggestive link-
age, the ASD regions for suggestive linkage (2q31, 3q26,
7q22, 7q36, 11p12-13, and 17q11) and those for ADHD
(5q13, 5q33, 6q12, 6q22-23, 7p13, 7q21, 9q22, 9q33,
11q22, 14q12, 15q15.1, 16p13, 16q23, 16q24, and 17p11)
show no overlap between ASD and ADHD [47]. If even
looser criteria are applied, linkage peaks for ADHD at
2q24, 9q33, 5p13, 15q, 16p1, 16p13, and 17p11 are in the
autistic-proximity of peaks previously detected in genome
scans for autism [44, 87]. If confirmed, such regions may
harbor pleiotropic genes for ADHD and ASD. The 16p13
peak was observed by Smalley et al. [89] in an ADHD
affected-sib-pair analysis in 203 families. They found a
significant linkage signal (maximum LOD 4.2) on a 12-cM
region on chromosome 16p13, a region already highlighted
in three genome scans for ASD. As yet, this linkage signal
and those on 5p13 [8, 49, 53, 67, 99] and 9q33 [8, 77, 84]
may appear to be the most fruitful loci to search for
pleiotropic genes, since both of these loci are supported
by at least two independent studies of autism (although
not necessarily genome wide significant), and at least
one study of ADHD. However, linkage studies of
ADHD ? ASD samples are warranted before firm con-
clusions can be drawn.
Genome-wide association studies (GWAS)
Molecular genetic studies are increasingly using genome-
wide association study (GWAS) designs. This new analytic
approach combines the power to detect genetic variants of
small effect size with the possibility to perform hypothesis-
free analyses of the entire genome [31]. In GWAS, 100,000
to over 1,000,000 single nucleotide polymorphisms (SNPs)
are genotyped across the genome and tested for their
association with the disorder. Given that GWA studies are
still in their very early beginning, it may be somewhat
premature to look for overlapping findings for ADHD and
ASD. Nevertheless, Franke et al. [31] recently reviewed the
GWAS literature for SNPs associated with ADHD and
several of the top-findings from the reviewed studies turned
out to be located near to linkage findings in ASD. A
summary of these findings for 16 SNPs possibly involved
in ASD is given in Table 1. Similarly, we reviewed the
literature for SNPs from SNP-based GWAS in ASD [54,
96; genome-wide ASD CNV studies were already men-
tioned above]. We report in Table 2 ASD GWAS findings
that may also be involved in ADHD. Twenty-five SNPs
related to ASD, may also be of interest to ADHD. As
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Table 1 Overview of single nucleotide polymorphisms (SNPs) among the top-findings of GWAS in ADHD possibly also involved in ASD
(based on Franke et al. [31])
SNP Chr Position
(bp)
Position Gene functiona Previous findings for ASDa
rs272000 2 116372265 Within 50 kb
downstream
of DPP10
Encodes dipeptyl peptidase 10, which does not
possess dipeptidyl peptidase activity, but
binds to specific voltage-gated potassium
channels and alters their expression and
biophysical properties. The expression of the
gene is highest in the brain.
The gene contains CNVs potentially
linked to autism [57].
rs10049246 3 187169435 Intron of
AK309325
Hypothetical gene of unknown function. SNP lies in a linkage region for autism
[57].
rs6791644 3 60746148 Intron of FHIT Encodes a diadenosine 50,50 0 0-P1,P3-
triphosphate hydrolase involved in purine
metabolism. FHIT has a major role in
regulating beta-catenin-mediated gene
transcription. Expression in many tissues
including the brain.
Gene is affected by CNVs in autism [57,
85].
rs10983238 9q33.1 118373504 Intron of ASTN2 Encodes astrotactin 2, a membrane protein
expressed in multiple tissues including the
brain. It is critically involved in neuron-glia
binding during the developmental periods of
glial-guided cell migration and assembly into
neuronal layers in the developing brain. A
homologue of the gene, ASTN, is involved in
neuronal migration.
The gene was found disrupted by rare
CNVs in patients with autism [57].
rs1764178 9 1046959 Coding exon of
DMRT2
Encodes doublesex and mab-3 related
transcription factor 2, a potential regulator of
sex differentiation. Expressed in multiple
tissues, including the brain.
Site is known for CNVs. Falls into/close
to a suggestive linkage region for
autism [1, 8].
rs3893215 11p15.1 17721406 Intron of
KCNC1
Encodes potassium voltage-gated channel
Shaw-related subfamily member 1, a protein
belonging to the delayed rectifier class of
channel proteins and an integral membrane
protein that mediates the voltage-dependent
potassium ion permeability of excitable
membranes.
The SNP is close to/within regions of
(suggestive) linkage to autism from a
meta-analysis [93] and primary studies
[8, 27].
rs874426 11 19526139 Intron of NAV2 Encodes neuron navigator 2, an retinoic acid-
responsive gene that seems to play a role in
neuronal development. It is highly expressed
in the fetal and adult brain.
The SNP is close to/within regions of
(suggestive) linkage to autism from a
meta-analysis [93] and primary studies
[8, 27].
rs7995215 13q31.3 93206507 Intron of GPC6 Encodes glypican 6. The glypicans comprise a
family of glycosylphosphatidylinositol-
anchored heparin sulfate proteoglycans. The
glypicans have been implicated in the control
of cell growth and division. Glypican 6 is a
putative cell surface coreceptor for growth
factors, extracellular matrix proteins,
proteases and anti-proteases. Expressed in
multiple tissues including the brain.
CNVs in the gene have been noted in a
study on autism [57].
rs2360997 14 75882244 Within 25 kb
upstream of
ESRRB
Encodes estrogen-related receptor beta, a
protein with similarity to the estrogen
receptor, expressed in brain and other tissues.
CNVs in the gene have been noted in a
study on autism [57].
rs7164335 15q23 66502086 ITGA11 Encodes integrin alpha 11. Integrins are
heterodimeric integral membrame proteins
composed of an alpha chain and a beta chain.
The gene is expressed in multiple tissues
including the brain.
The SNP lies close to linkage regions for
autism [8].
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already indicated above, (rare) CNVs might also indicate
genes pleiotropic for ASD and ADHD.
Summary of shared heritability findings for ADHD
and ASD
Family based studies in clinical ADHD samples indicate
that ASD symptoms are familial within ADHD families,
and possibly related to similar familial origins as the
ADHD symptoms. Twin studies suggest that 50-72% of the
phenotypic variance may be attributable to shared additive
genetic factors. It appears that findings are robust for
influences of gender, albeit inconsistent results are reported
concerning this issue in family based studies on the one
hand (more familial in males in one study and more
familial in females in another study) and twin studies on
the other hand (no effect of gender). In addition, age may
have an effect with shared heritability estimates possibly
increasing with older age. A few candidate gene studies
have examined the association with candidate genes for
one disorder in relationship to the other disorder. DAT1,
DRD3, DRD4, COMT and MAOA (ADHD candidate
genes) have been examined for their association with ASD.
Findings for DRD4 were negative, for DAT1 and COMT
inconclusive, and for DRD3 and MAOA at best cautiously
positive. Serotonin related genes (ASD candidate genes)
may be related to ADHD as well, yet no uniform picture
emerges (reviewed elsewhere [87]). However, these can-
didate gene studies are largely underpowered, prohibiting
firm conclusions regarding these findings. In some cases,
rare mutations (such as copy number variations (CNVs),
Table 1 continued
SNP Chr Position
(bp)
Position Gene functiona Previous findings for ASDa
rs2677744 15q26.1 89251445 Intron of
MAN2A2
Encodes mannosidase, alpha, class 2a, member
2, expressed in the brain and many other
tissues. The protein is involved in N-glycan
synthesis.
SNP lies close to linkage regions for
autism [8].
rs1471225 15 27675688 Within 30 kb
downstream
of KIAA0574
Encodes protein of unknown function
expressed in the brain and other tissues.
The site is found in CNV regions in 3
studies of autism [22, 57, 85].
rs7495052 15 90353033 Intron of
SLCO3A1
Encodes solute carrier organic anion transporter
family, member 3A1, which might be
involved in the regulation of extracellular
vasopressin concentration in the human brain
and thus might influence the neuromodulation
of neurotransmission by cerebral
neuropeptides such as vasopressin.
In/near suggestive linkage regions for
autism [8].
rs7187223 16 81015234 Intergenic,
within 203 kb
upstream from
CDH13
Encodes cadherin 13, a member of the cadherin
superfamily. The encoded protein is a
calcium-dependent cell–cell adhesion
glycoprotein. This particular cadherin is a
putative mediator of cell–cell interaction in
the heart and may act as a negative regulator
of neural cell growth.
The gene shows CNVs potentially
related to autism [22].
rs6565113 16 81665146 Intron of
CDH13
See above See above
rs4810685 20 45834120 Intron of
SULF2
Encodes heparin sulfatase 2. Heparan sulfate
proteoglycans (HSPGs) act as coreceptors for
numerous heparin-binding growth factors and
cytokines and are involved in cell signaling.
SULF2 can change properties of the
coreceptors by removing sulfate moieties.
The gene is essential for mammalian
development and survival, it shows
ubiquitous expression.
The SNP lies close to a linkage region
for autism [1].
a Where not indicated otherwise, the information is derived from the UCSC Browser, NCBI’s OMIM, Gene and Unigene databases, and the
Sullivan Lab Evidence Project website (location of SNP expanded by ±5 Mb for genome-wide linkage scans, ±5 kb for GWAS, microarray and
CNV studies, and ± 50 kb for signposts)
ADHD attention-deficit/hyperactivity disorder, ASD autism spectrum disorders, CNV copy number variation, SNP single nucleotide
polymorphism
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Table 2 Overview of single nucleotide polymorphisms (SNPs) among the published top-findings of GWAS in ASD which may also be involved
in ADHD
SNP/CNV Chr Position (bp) Position Gene functiona Previous findings for ADHDa
Wang et al. [96]
6 SNPs 5p14.1 25934678–
26008578
Between CDH9 and
CDH10
The genes encode type II classical cadherins
from the cadherin superfamily, integral
membrane proteins that mediate calcium-
dependent cell–cell adhesion. Both are
expressed in brain.
The SNPs lie close to a linkage
region for ADHD [44].
rs9395885,
rs9349688
6p12.1 53853436–
53870051
Within intron of
LRRC1
Ecodes leucine-rich repeat-containing protein 1,
a membrane protein of unknown function
found in epithelia (and brain).
The SNPs are within a region
of suggestive linkage to
ADHD from a meta-analysis
[101].
rs9384952 6p22.1 116066757 Intergenic The SNPs are within a region
of suggestive linkage to
ADHD from a meta-analysis
[101].
8 SNPs 13q33.3 108823637–
108881899
Within 200 kb
downstream of
MYO16
Encodes myosin heavy chain Myr 8, a gene
highly expressed in brain. This cytoskeletal
motor protein is involved in brain (especially
cerebellum) development.
The SNPs lie close to
suggestive linkage result for
ADHD [9].
rs9932538 16p12.3 19116070 Within intron of
SYT17
The product of this gene, synaptotagmin XVII
(or B/K protein), is involved in vesicle
transport and is highly expressed in brain,
especially in the frontal and temporal lobes, the
hippocampus, the hypothalamus, the
amygdala, the substantia nigra, and the
pituitary [21]
The SNP lies close to
significant linkage result for
ADHD [67].
Ma et al. [54]b
5 SNPs 5p14 25934777–
25970827
Between CDH9 and
CDH10
The genes encode type II classical cadherins
from the cadherin superfamily, integral
membrane proteins that mediate calcium-
dependent cell–cell adhesion. Both are
expressed in brain. See also above, same
findings reported by Wang et al. [96].
The SNPs lie close to a linkage
region for ADHD [44].
rs2528795 7 73111430 Within intron of ELN This gene encodes the elastin isoform a
precursor. The mature protein that is one of the
two components of elastic fibers. The encoded
protein is rich in hydrophobic amino acids such
as glycine and proline, which form mobile
hydrophobic regions bounded by crosslinks
between lysine residues. Deletions and
mutations result in severe anomalies of the
aorta and skin, but the gene also falls into the
deletion found in Williams Beuren syndrome.
The latter is a contiguous gene syndrome with
neurobehavioral features and mental
retardation not easily accounted for by the
disruption of the elastin gene alone.
The SNP lies within suggestive
linkage region for ADHD
from meta-analysis [101].
rs171415 20 58229934 Within intron of
hypothetical genes
AX747739 and
AK309218
Hypothetical gene(s) of unknown function. Less than 10 kb from one of
the top-findings of GWAS
for ADHD [63].
ADHD attention-deficit/hyperactivity disorder, ASD autism spectrum disorders, CNV copy number variation, SNP single nucleotide
polymorphism
a Where not indicated otherwise, the information is derived from the UCSC Browser, NCBI’s OMIM, Gene and Unigene databases, and the
Sullivan Lab Evidence Project website (location of SNP expanded by ±5 Mb for genome-wide linkage scans, ±5 kb for GWAS, microarray and
CNV studies, and ±50 kb for signposts)
b Analysis was limited to SNPs showing p-values of 10-4 or smaller in the combined analysis of discovery and replication dataset
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premutations in the 50 untranslated region of the FMR1
gene on the X-chromosome, segmental duplications at
breakpoints (BP4-BP5) of chromosome 15q13.2-q13.3, a
deletion of 22q11 containing the COMT gene, and the rare
XXYY syndrome) may account for some ADHD ? ASD
cases. However, given that these syndromes are mostly
accompanied by characteristic physical abnormalities, they
are unlikely to account for many ADHD ? ASD cases
without clear medical cause. With the exception of one
study, only an indirect comparison of candidate linkage
loci for ADHD and ASD can be made, since all loci are
based on studies including patients with either ADHD or
ASD. Limited evidence for overlap is found for overlap-
ping suggestive linkage signals for ADHD and ASD. When
applying looser criteria, 5p13, 9q33, and 16p13 appear to
be the most fruitful loci to search for pleiotropic genes.
With respect to GWAS findings, 16 SNPs related to ADHD
may possibly involved in ASD and 25 SNPs related to ASD
may also be of interest to ADHD. However, GWA studies
are still in their very early beginning, so it may be some-
what premature to look for overlapping findings for ADHD
and ASD.
Recommendations for future genetic studies
of ADHD 1 ASD
GWAS have provided us with a tool to identify new genes
for multifactorial disorders like ASD and ADHD. These
studies require large samples to be investigated, with
thousands of cases and equal numbers of controls to be
analyzed. For this, international collaborations are being
formed; one of the largest ones for psychiatric disorders
being the Psychiatric GWAS Consortium [74]. One of the
three main objectives of the Psychiatric GWAS Consor-
tium is ‘‘cross-disorder analyses, including analyses of
combinations of disorders and of phenotypes observed in
two or more disorders … based on recommendations of an
expert committee. Because data are insufficient to deter-
mine what common cross-disorder etiological factors
might exist, alternative phenotypes should be explored.
GWAS analyses have produced surprising cross-disorder
associations, such as those found for cancers and inflam-
matory bowel diseases, which could also exist for psychi-
atric disorders given the many common symptoms’’ (p. 548
[73]). No such cross-disorder analyses have been con-
ducted for ADHD in combination with ASD. Therefore, we
will propose several steps for future research that may
facilitate the detection of pleiotropic etiological factors for
ADHD and ASD.
A first step in future family genetic studies on the shared
etiology of ADHD and ASD would be to assess ADHD and
ASD in both parents and (multiple) off-spring. If parents
and children are assessed using comparable phenotypic
measures, a more direct examination can be made for inter-
generational transmission of ADHD, ASD, and
ADHD ? ASD symptoms. It is of crucial importance to
include not only categorical measures of ADHD and ASD
into this design, but also to make use of quantitative phe-
notypic measures. The latter does more justice to the
quantitative nature of both disorders; individuals with
subthreshold symptoms are otherwise grouped together
with individuals with no symptoms. Two types of families
would be suitable for this approach: families in which the
disorders are separately present in different family mem-
bers, and families in which members are affected with both
disorders, simultaneously. Both types of families may
provide insight into pleiotropic genes and genes that are
uniquely associated with one of both disorders: the former
through simultaneously regressing gene effects on the
ADHD and ASD phenotypes within families, the latter
through regressing gene effects on the ADHD and ASD
phenotypes within individuals.
A second (or parallel) step would be to assess candidate
endophenotypes within a family-based design in which
both ADHD and ASD are present in one or more family
members. Endophenotypes, such as neuroimaging or neu-
ropsychological functions, are defined as heritable vulner-
ability traits that form a link between genes and observable
symptoms [39]. The first generation of ADHD and ASD
GWAS studies using the ASD or ADHD clinical pheno-
types made it clear that psychiatric diagnostic phenotypes
may not be optimally suited for gene discovery. Compared
to phenotypes, endophenotypes may improve statistical
power by (a) being more heritable than phenotypes, (b)
being more easily quantifiable than dichotomous DSM
diagnostic categories, (c) being more reliable and objective
than phenotypic measures, (d) being more biologically
relevant, and (e) being more useful in creating genetically
homogeneous subgroups of patients. Candidate endophe-
notypes for ADHD ? ASD would most likely show the
following characteristics: (a) more impaired in
ADHD ? ASD probands compared to ADHD or ASD
probands, (b) more impaired in parents and siblings of
ADHD ? ASD-probands compared to those of ADHD or
ASD probands, (c) stronger correlation between siblings in
ADHD ? ASD families compared to those in ADHD or
ASD families, (d) cross-correlating with both ADHD and
ASD in family members. In extensive review on candidate
ADHD ? ASD endophenotypes (Rommelse et al. sub-
mitted), we concluded that executive functioning, response
variability, social cognition, motor coordination, language
and intelligence are the most promising candidate neuro-
psychological endophenotypes. Candidate structural brain
endophenotypic measurements include overall brain size,
corpus callosum and cerebellum size, and structural
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integrity of the fronto-striatal circuitry. Too little data
existed on functional brain imaging measures to propose
candidate endophenotypes in this domain. Body parameters
that may be useful for future studies are finger length ratio,
height and weight and, possibly, fatty acid abnormalities.
By incorporating these candidate endophenotypes into
molecular genetic studies, both statistical power as well as
insight into gene-behavior pathways may be gained.
However, the endophenotype approach is not without its
shortcomings. For example, it is not well established that
endophenotypes are indeed more reliable and objective
than clinical phenotypes [11]. Furthermore, a putative
endophenotype might not be less ‘genetically complex’ or
more heritable than the phenotype itself [11], thereby not
automatically resulting in an increased power to detect
genetic effects. For example, though useful [78] and
potentially more powerful than studies of clinical pheno-
types, quite substantial sample sizes are still needed when
endophenotypes at the level of neurocognitive performance
are used for genetic studies [11]. However, structural and
functional neuroimaging measures do appear to be able to
reduce necessary sample sizes for molecular genetic anal-
yses considerably [58, 62]. Therefore, despite possible
shortcomings, we would nevertheless recommend incor-
porating candidate endophenotypic measures in family-
genetic research for ADHD ? ASD.
Another recommendation is to analyze multiple endo-
phenotypes at the same time. This could be achieved by
combining related traits into a single outcome using prin-
cipal component analyses or factor analyses. Hereby
common underlying constructs are extracted based on
covariance between measures while the number of vari-
ables is reduced. Main advantages over the use of multiple
correlated endophenotypes in univariate analyses are an
increased reliability and decreased risk of false positive
results. A potential disadvantage of this approach may be
the loss of information by removing variance that is spe-
cific to each of the endophenotypes. Alternatively, multi-
variate multi-level models may be used. Multivariate
multi-level models flesh out the relationships between
numerous intermediate phenotypes [82]. Using this tech-
nique, multiple explanatory genetic variables can be
simultaneously included in the model (multivariately) and
regressed on variables measured at the endophenotype and
phenotype level. As most cases of ADHD and ASD are
probably caused by many genes of small individual effect,
incorporating the relationships between multiple genes,
endophenotypes and the clinical phenotypes in the model
are even more important. The multivariate endophenotype
approach has already proved useful in various other
domains of endophenotypic research [13, 71, 97] and will
most likely prove fruitful in the search for common etio-
logical factors for ADHD ? ASD.
Last but not least, the effect of environmental variables
on endophenotypic and phenotypic functioning should not
be overlooked. A candidate endophenotype can be asso-
ciated with a diagnosis, be heritable and be reliably
assessed, but nevertheless be under (strong) influence of
environmental factors. Gene–environment interactions
(mainly related to early/obstetric variables) on the pheno-
type are increasingly reported in ADHD and ASD literature
[12, 60, 68, 90, 91; see also elsewhere in this issue] and
may also exist for endophenotypes. Therefore, gene–envi-
ronment interactions are of vital importance to take into
consideration when studying a common etiological basis
for both disorders.
In sum, properly designed and powered candidate gene
and linkage studies are missing for ADHD ? ASD.
Recent GWAS for clinical ADHD and ASD phenotypes
have identified a number of viable pleiotropy candidates.
GWAS currently seem to be the most appropriate
approaches to learn about the role of common genetic
variants in the combined disorders. We propose that
future studies examining shared familial etiological fac-
tors for ADHD and ASD (a) use a family-based design in
which the same measurements are obtained from all
family members, (b) incorporate a coherent set of candi-
date endophenotypic measures that are most likely shared
risk factors for ADHD and ASD, (c) apply multivariate
multi-level models for statistical analysis, in order to
examine the relationships between the various endophe-
notypes and phenotypes, and (d) incorporate environ-
mental measures into the design.
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